新華錦(600735.SH):不再持有招金期貨任何股權
格隆匯12月30日丨新華錦(600735.SH)公佈,此前披露,公司於2021年5月31日召開了第十二屆董事會第十七次會議,審議通過了《關於轉讓招金期貨有限公司20.04%股權的議案》,公司以6943.86萬元的交易對價向淄博市財金控股集團有限公司轉讓公司持有的招金期貨有限公司(“招金期貨”)20.04%股權,此次交易需期貨行業監管部門批准。
近日,招金期貨已經取得中國證監會《關於核准招金期貨有限公司變更股權的批覆》(證監許可[2021]4050 號),此次股權轉讓涉及的期貨行業監管部門審批及工商變更手續已經完成,公司已收到此次股權轉讓的全部交易對價款。至此,公司不再持有招金期貨任何股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.